C. Sturgeon, Practice guidelines for tumor marker use in the clinic, Clin Chem, vol.48, pp.1151-1160, 2002.

B. You and G. Freyer, Du bon usage des principaux biomarqueurs tumoraux, Maloine Diagnostic difficile en médecine interne, 2008.

G. Aus, S. Bergdahl, R. Frosing, P. Lodding, E. Pileblad et al., Reference range of prostate-specific antigen after transurethral resection of the prostate, Urology, vol.47, issue.4, pp.529-560, 1996.
DOI : 10.1016/S0090-4295(99)80489-0

F. Recker, M. Kwiatkowski, and K. Pettersson, Enhanced Expression of Prostate-Specific Antigen in the Transition Zone of the Prostate, European Urology, vol.33, issue.6, pp.549-55, 1998.
DOI : 10.1159/000019654

H. Lilja, D. Ulmert, and A. Vickers, Prostate-specific antigen and prostate cancer: prediction, detection and monitoring, NatRevCancer, vol.8, pp.268-78, 2008.

N. Mottet, N. Berger, and J. Droz, Diagnosis and staging of germ-cell tumours of the testis], RevPrat, vol.57, pp.365-78, 2007.

N. Voorzanger-rousselot and P. Garnero, Biochemical markers in oncology. Part I: Molecular basis. Part II: Clinical uses, Cancer Treatment Reviews, vol.33, issue.3, pp.230-83, 2007.
DOI : 10.1016/j.ctrv.2007.01.008

A. Gadducci, S. Cosio, A. Carpi, A. Nicolini, and A. Genazzani, Serum tumor markers in the management of ovarian, endometrial and cervical cancer, Biomedicine & Pharmacotherapy, vol.58, issue.1, pp.24-38, 2004.
DOI : 10.1016/j.biopha.2003.11.003

A. Rapkiewicz, V. Espina, E. Petricoin, I. Liotta, L. Park et al., Biomarkers of ovarian tumours Experience of 1446 rectal cancer patients in Korea and analysis of prognostic factors, EurJCancer IntJColorectal Dis, vol.4014, issue.10, pp.2604-12101, 1999.

W. Wang, J. Lin, and T. Chiou, Preoperative carcinoembryonic antigen level as an independent prognostic factor in colorectal cancer: Taiwan experience 2 New tumor markers: CA125 and beyond, JpnJClin Oncol IntJGynecolCancer, vol.3015, pp.12-6274, 2000.

S. Paramasivam, L. Tripcony, and A. Crandon, Prognostic importance of preoperative CA-125 in International Federation of Gynecology and Obstetrics stage I epithelial ovarian cancer: an Australian multicenter study Can the preoperative Ca-125 level predict optimal cytoreduction in patients with advanced ovarian carcinoma? A single institution cohort study The prognostic value of pretreatment CA 125 in patients with advanced ovarian carcinoma: a Gynecologic Oncology Group study, JClinOncol Gynecol Oncol Cancer, vol.23112115, issue.15, pp.5938-4211, 2005.

K. Jeng, I. Sheen, and Y. Tsai, Does the presence of circulating hepatocellular carcinoma cells indicate a risk of recurrence after resection? International Germ Cell Consensus Classification: a prognostic factor-based staging system for metastatic germ cell cancers. International Germ Cell Cancer Collaborative Group Clinical practice guidelines for the use of tumor markers in breast and colorectal cancer, AmJGastroenterol JClinOncol JClin Oncol, vol.991514, issue.18, pp.1503-9594, 1996.

M. Gion, P. Boracchi, and R. Dittadi, Prognostic role of serum CA15.3 in 362 nodenegative breast cancers. An old player for a new game 5, EurJCancer, vol.38, issue.20, pp.1181-1189, 2002.

M. Uehara, T. Kinoshita, T. Hojo, S. Akashi-tanaka, E. Iwamoto et al., Long-term prognostic study of carcinoembryonic antigen (CEA) and carbohydrate antigen 15-3 (CA 15-3) in breast cancer, International Journal of Clinical Oncology, vol.110, issue.5, pp.2521-7447, 1998.
DOI : 10.1007/s10147-008-0773-3

N. Eche, M. Pichon, and V. Quillien, Standards, options and recommendations for tumor markers in colorectal cancer], BullCancer, vol.88, pp.1177-206, 2001.

M. Kouri, S. Nordling, P. Kuusela, and S. Pyrhonen, Poor prognosis associated with elevated serum CA 19-9 level in advanced colorectal carcinoma, independent of DNA ploidy or SPF, European Journal of Cancer, vol.29, issue.12, pp.1691-1697, 1993.
DOI : 10.1016/0959-8049(93)90106-P

V. Hess, B. Glimelius, and P. Grawe, CA 19-9 tumour-marker response to chemotherapy in patients with advanced pancreatic cancer enrolled in a randomised controlled trial, The Lancet Oncology, vol.9, issue.2, pp.132-140, 2008.
DOI : 10.1016/S1470-2045(08)70001-9

W. Steinberg, The clinical utility of the CA 19-9 tumor-associated antigen 2

M. Reni, S. Cereda, and G. Balzano, Carbohydrate antigen 19-9 change during chemotherapy for advanced pancreatic adenocarcinoma CYFRA 21-1 is a prognostic determinant in nonsmall-cell lung cancer: results of a meta-analysis in 2063 patients, Cancer Pujol JL BrJCancer, vol.11590, issue.27, pp.2630-92097, 2004.

G. Torre, F. Nobels, D. Kwekkeboom, and W. Coopmans, 29. FIGO staging for gestational trophoblastic neoplasia FIGO Oncology Committee Chromogranin A as serum marker for neuroendocrine neoplasia: comparison with neuron-specific enolase and the alphasubunit of glycoprotein hormones Postoperative nomogram for disease recurrence after radical prostatectomy for prostate cancer, TumourBiol IntJ GynaecolObstet JClinEndocrinolMetab JClinOncol, vol.19778217, issue.32, pp.517-26285, 1997.
URL : https://hal.archives-ouvertes.fr/hal-01428105

M. Han, A. Partin, M. Zahurak, S. Piantadosi, J. Epstein et al., Biochemical (Prostate Specific Antigen) Recurrence Probability Following Radical Prostatectomy for Clinically Localized Prostate Cancer, The Journal of Urology, vol.169, issue.2, pp.517-540, 2003.
DOI : 10.1016/S0022-5347(05)63946-8

J. Bonner, J. Sloan, K. Rowland, and . Jr, Significance of neuron-specific enolase levels before and during therapy for small cell lung cancer CA-125 change after chemotherapy in prediction of treatment outcome among advanced mucinous and clear cell epithelial ovarian cancers: a Gynecologic Oncology Group study, ClinCancer Res Cancer, vol.6115, issue.34, pp.597-6011395, 2000.

R. Rocconi, K. Matthews, M. Kemper, K. Hoskins, W. Huh et al., The timing of normalization of CA-125 levels during primary chemotherapy is predictive of survival in patients with epithelial ovarian cancer, Gynecologic Oncology, vol.114, issue.2, pp.242-247, 2009.
DOI : 10.1016/j.ygyno.2009.04.019

C. Wong, Z. Dai, S. Lele, and N. Natarajan, Comparison of CA 125 after three courses of chemotherapy and results of second-look surgery, Eur J Gynaecol Oncol, vol.21, pp.70-73, 2000.

T. Le, W. Faught, L. Hopkins, and M. Fung-kee-fung, The Importance of CA125 Normalization During Neoadjuvant Chemotherapy Followed by Planned Delayed Surgical Debulking in Patients With Epithelial Ovarian Cancer, Journal of Obstetrics and Gynaecology Canada, vol.30, issue.8, pp.665-70, 2008.
DOI : 10.1016/S1701-2163(16)32914-0

S. Tate, Y. Hirai, N. Takeshima, K. Hasumi, P. Hoskins et al., CA125 regression during neoadjuvant chemotherapy as an independent prognostic factor for survival in patients with advanced ovarian serous adenocarcinoma, Gynecologic Oncology, vol.96, issue.1, pp.143-152, 2005.
DOI : 10.1016/j.ygyno.2004.09.020

F. Motoi, T. Rikiyama, Y. Katayose, S. Egawa, M. Unno et al., Retrospective Evaluation of the Influence of Postoperative Tumor Marker Status on Survival and Patterns of Recurrence After Surgery for Pancreatic Cancer Based on RECIST Guidelines Value of CA 15.3 in breast cancer and comparison with CEA and TPA: a study of specificity in disease-free follow-up patients and sensitivity in patients at diagnosis of the first metastasis Serum CEA, CA 15-3, and MCA in breast cancer patients: a clinical evaluation Decline of posttreatment tumor marker levels after therapy of nonsmall cell lung cancer. A useful outcome predictor, Serum squamous cell carcinoma antigen levels in invasive cervical cancer: prediction of response and recurrence, pp.209-16411, 1993.

J. Riedinger, J. Wafflart, and G. Ricolleau, CA 125 half-life and CA 125 nadir during induction chemotherapy are independent predictors of epithelial ovarian cancer outcome: results of a French multicentric study, Annals of Oncology, vol.17, issue.8, pp.942-948, 1993.
DOI : 10.1093/annonc/mdl120

S. Kang, S. Seo, P. Sy-parera, M. Peralta, and S. , Nadir CA-125 level is an independent prognostic factor in advanced epithelial ovarian cancer, Journal of Surgical Oncology, vol.20, issue.3, pp.244-251, 2009.
DOI : 10.1002/jso.21258

P. Liu, D. Alberts, B. Monk, M. Brady, J. Moon et al., An Early Signal of CA-125 Progression for Ovarian Cancer Patients Receiving Maintenance Treatment After Complete Clinical Response to Primary Therapy, Journal of Clinical Oncology, vol.25, issue.24, pp.3615-3635, 2007.
DOI : 10.1200/JCO.2006.09.4540

H. Sandler, R. Dunn, P. Mclaughlin, J. Hayman, M. Sullivan et al., Overall survival after prostate-specific-antigen-detected recurrence following conformal radiation therapy ng/mL defines disease freedom after radiotherapy for prostate cancer using modern techniques, Int J Radiat Oncol Biol Phys Urology, vol.4854, issue.2, pp.629-33968, 1999.

L. Kestin, F. Vicini, E. Ziaja, J. Stromberg, R. Frazier et al., Defining biochemical cure for prostate carcinoma patients treated with external beam radiation therapy, Cancer, vol.72, issue.8, pp.1557-66, 1999.
DOI : 10.1002/(SICI)1097-0142(19991015)86:8<1557::AID-CNCR24>3.0.CO;2-2

A. Martinez, L. Kestin, and J. Stromberg, Interim report of image-guided conformal high-dose-rate brachytherapy for patients with unfavorable prostate cancer: the William Beaumont phase II dose-escalating trial The PSA nadir that indicates potential cure after radiotherapy for prostate cancer Postoperative radiotherapy for localized prostate cancer: clinical significance of nadir prostate-specific antigen value within 12 months, Int J Radiat Oncol Biol Phys Urology Anticancer Res, vol.474929, issue.55, pp.343-52322, 1997.

V. Kavadi, G. Zagars, and A. Pollack, Serum prostate-specific antigen after radiation therapy for clinically localized prostate cancer: Prognostic implications, International Journal of Radiation Oncology*Biology*Physics, vol.30, issue.2, pp.279-87, 1994.
DOI : 10.1016/0360-3016(94)90005-1

I. Aref, L. Eapen, O. Agboola, and P. Cross, The relationship between biochemical failure and time to nadir in patients treated with external beam therapy for T1-T3 prostate carcinoma, Radiotherapy and Oncology, vol.48, issue.2, pp.203-210, 1998.
DOI : 10.1016/S0167-8140(98)00061-9

K. Doyle, M. Roach, V. Weinberg, P. Mclaughlin, H. Sandler et al., What Does the Post Radiotherapy Prostate Specific Antigen (PSA) Nadir Tell Us About Progression-Free- Survival in Patients with Localized Cancer Phys;51. 60. Buyyounouski MK. Radiotherapy: PSA nadir predicts long-term mortality Early prostate-specific antigen (PSA) kinetics following prostate carcinoma radiotherapy: prognostic value of a time-and-PSA threshold model, Int J Radiat Oncol Biol Nat Rev Clin Oncol Cancer, vol.7101, issue.61, pp.188-9096, 2004.

D. Kuban, L. Levy, and L. Potters, Comparison of biochemical failure definitions for permanent prostate brachytherapy Postoperative prostate-specific antigen nadir improves accuracy for predicting biochemical recurrence after radical prostatectomy: Results from the Shared Equal Access Regional Cancer Hospital (SEARCH) and Duke Prostate Center databases Prognostic significance of undetectable ultrasensitive prostate-specific antigen nadir after radical prostatectomy, Int J Radiat Oncol Biol Phys Int J Urol Urology, vol.6576, issue.64, pp.1487-93723, 2006.

A. Stephenson, M. Kattan, and J. Eastham, Defining Biochemical Recurrence of Prostate Cancer After Radical Prostatectomy: A Proposal for a Standardized Definition, Journal of Clinical Oncology, vol.24, issue.24, pp.3973-3981, 2006.
DOI : 10.1200/JCO.2005.04.0756

S. Hori, T. Jabbar, N. Kachroo, J. Vasconcelos, C. Robson et al., Outcomes and predictive factors for biochemical relapse following primary androgen deprivation therapy in men with bone scan negative prostate cancer Is biochemical response more important than duration of neoadjuvant hormone therapy before radiotherapy for clinically localized prostate cancer? An analysis of the 3-versus 8-month randomized trial, J Cancer Res Clin Oncol Int J Radiat Oncol Biol Phys, vol.6776, pp.23-30, 2010.

J. Morote, E. Trilla, S. Esquena, J. Abascal, R. J. Soga et al., Nadir prostate-specific antigen best predicts the progression to androgen-independent prostate cancer Undetectable level of prostate specific antigen (PSA) nadir predicts PSA biochemical failure in local prostate cancer with delayed-combined androgen blockade, Int J Cancer Jpn J Clin Oncol, vol.10838, issue.69, pp.877-81617, 2004.

G. Lin, X. Yao, and S. Zhang, Prostate-specific antigen half-life: a new predictor of progression-free survival and overall survival in Chinese prostate cancer patients, Asian Journal of Andrology, vol.11, issue.4, pp.443-50, 2009.
DOI : 10.1038/aja.2008.36

M. Kobayashi, K. Suzuki, S. Kurokawa, M. Yuzawa, T. Morita et al., Second-Line Antiandrogen Therapy in Japanese Men with Advanced Prostate Cancer Relapsed after Primary Combined Androgen Blockade: Who Will Benefit from Second-Line Hormonal Therapy? Prognostic value of CA 19-9 levels in patients with carcinoma of the pancreas treated with radiotherapy, Urol Int Int J Radiat Oncol Biol Phys, vol.7241, pp.393-399, 1998.

J. Grem, S. Steinberg, and A. Chen, The utility of monitoring carcinoembyronic antigen during systemic therapy for advanced colorectal cancer Defining the ideal cutpoint for determining PSA recurrence after radical prostatectomy. Prostate-specific antigen A Gynecologic Oncology Group Study of serum CA-125 levels in patients with stage III optimally debulked ovarian cancer treated with intraperitoneal compared to intravenous chemotherapy: an analysis of patients enrolled in GOG 172, Oncol Rep Urology Gynecol Oncol, vol.561115, issue.75, pp.559-67365, 1998.

N. Kondo, Y. Murakami, and K. Uemura, Prognostic impact of perioperative serum CA 19-9 levels in patients with resectable pancreatic cancer Early identification of resistance to first-line single-agent methotrexate in patients with persistent trophoblastic disease, Ann Surg Oncol J Clin Oncol, vol.1724, issue.78, pp.2321-952, 2006.

L. Kerkmeijer, C. Thomas, and R. Harvey, External validation of serum hCG cutoff levels for prediction of resistance to single-agent chemotherapy in patients with persistent trophoblastic disease, British Journal of Cancer, vol.104, issue.6, pp.979-84, 2009.
DOI : 10.1200/JCO.2005.03.3043

M. Markman, P. Liu, M. Rothenberg, B. Monk, M. Brady et al., Pretreatment CA-125 and risk of relapse in advanced ovarian cancer Postresection CA 19-9 predicts overall survival in patients with pancreatic cancer treated with adjuvant chemoradiation: a prospective validation by RTOG 9704 Practical issues in the management of low-risk gestational trophoblast tumors, J Clin Oncol J Clin Oncol J Reprod Med, vol.242653, issue.82, pp.1454-85918, 2006.

G. Rustin, A. Nelstrop, and P. Mcclean, Defining response of ovarian carcinoma to initial chemotherapy according to serum CA 125 Retrospective analysis of weekly topotecan as salvage therapy in relapsed ovarian cancer, J Clin Oncol Bhoola SM Gynecol Oncol, vol.1495, issue.84, pp.1545-51564, 1996.

L. Bodnar, G. Wcislo, and A. Nasilowska, Salvage therapy with topotecan in heavily pretreated ovarian cancer patients Change in CA 125 levels after the first cycle of induction chemotherapy is an independent predictor of epithelial ovarian tumour outcome, J Cancer Res Clin Oncol AnnOncol, vol.13518, issue.86, pp.815-21881, 2007.

J. Kurebayashi, R. Nishimura, and K. Tanaka, Significance of serum tumor markers in monitoring advanced breast cancer patients treated with systemic therapy: a prospective study The use of blood tumour markers in the monitoring of metastatic breast cancer unassessable for response to systemic therapy Continuous chemotherapy in responsive metastatic breast cancer: a role for tumour markers Objective measurement of therapeutic response in breast cancer using tumour markers, Breast Cancer Breast Cancer Res Treat Br J Cancer Br J Cancer, vol.11676864, issue.89, pp.389-95273, 1991.

C. Ziske, C. Schlie, and M. Gorschluter, Prostatespecific antigen as a measure of disease outcome in metastatic hormone-refractory prostate cancer Post-therapy serum prostate-specific antigen level and survival in patients with androgen-independent prostate cancer Change in serum prostate-specific antigen as a marker of response to cytotoxic therapy for hormone-refractory prostate cancer Eligibility and response guidelines for phase II clinical trials in androgen-independent prostate cancer: recommendations from the Prostate- Specific Antigen Working Group Serum prostate-specific antigen decline as a marker of clinical outcome in hormone-refractory prostate cancer patients: association with progression-free survival, pain end points, and survival, Prognostic value of CA 19-9 levels in patients with inoperable. 93. Scher HI al. Estramustine plus docetaxel as second-line therapy in patients with hormone-refractory prostate cancer resistant to docetaxel alone, pp.1413-1420, 1993.

D. Lorenzo, G. Buonerba, C. Faiella, and A. , Phase II study of docetaxel re-treatment in docetaxel-pretreated castration-resistant prostate cancer, BJU International, vol.14, issue.2, 2010.
DOI : 10.1111/j.1464-410X.2010.09498.x

D. Lorenzo, G. Pizza, C. Autorino, and R. , Weekly Docetaxel and Vinorelbine (VIN-DOX) as First Line Treatment in Patients with Hormone Refractory Prostate Cancer, European Urology, vol.46, issue.6, pp.712-718, 2004.
DOI : 10.1016/j.eururo.2004.08.022

J. Ferrero, C. Foa, and S. Thezenas, A Weekly Schedule of Docetaxel for Metastatic Hormone-Refractory Prostate Cancer, Oncology, vol.66, issue.4, pp.281-288, 2004.
DOI : 10.1159/000078328

S. Fossa, A. Jacobsen, and C. Ginman, Weekly Docetaxel and Prednisolone versus Prednisolone Alone in Androgen-Independent Prostate Cancer: A Randomized Phase II Study, European Urology, vol.52, issue.6, pp.1691-1699, 2007.
DOI : 10.1016/j.eururo.2007.01.104

T. Kojima, T. Shimazui, and M. Onozawa, Weekly Administration of Docetaxel in Patients with Hormone-refractory Prostate Cancer: a Pilot Study on Japanese Patients, Japanese Journal of Clinical Oncology, vol.34, issue.3, pp.137-178, 2004.
DOI : 10.1093/jjco/hyh021

R. Manikandan, S. Srirangam, E. Pearson, S. Brown, O. Reilly et al., Diethylstilboestrol versus Bicalutamide in Hormone Refractory Prostate Carcinoma: A Prospective Randomized Trial, Urologia Internationalis, vol.75, issue.3, pp.217-238, 2005.
DOI : 10.1159/000087797

C. Nabhan, T. Lestingi, and A. Galvez, Erlotinib Has Moderate Single-agent Activity in Chemotherapy-na??ve Castration-resistant Prostate Cancer: Final Results of a Phase II Trial, Urology, vol.74, issue.3, pp.665-71, 2009.
DOI : 10.1016/j.urology.2009.05.016

D. Savarese, S. Halabi, and V. Hars, Phase II Study of Docetaxel, Estramustine, and Low-Dose Hydrocortisone in Men With Hormone-Refractory Prostate Cancer: A Final Report of CALGB 9780, Journal of Clinical Oncology, vol.19, issue.9, pp.2509-2525, 2001.
DOI : 10.1200/JCO.2001.19.9.2509

E. Small, J. Fontana, and N. Tannir, A phase II trial of gefitinib in patients with non-metastatic hormone-refractory prostate cancer, BJU International, vol.23, issue.4, pp.765-774, 2007.
DOI : 10.2165/00002018-200427140-00002

H. Kim, Y. Park, and M. Park, Clinical significance of a serum CA15-3 surge and the usefulness of CA15-3 kinetics in monitoring chemotherapy response in patients with metastatic breast cancer, Breast Cancer Research and Treatment, vol.26, issue.1, pp.89-97, 2009.
DOI : 10.1007/s10549-009-0377-2

R. Buller, S. Vasilev, and P. Disaia, CA 125 kinetics: A cost-effective clinical tool to evaluate clinical trial outcomes in the 1990s, American Journal of Obstetrics and Gynecology, vol.174, issue.4, pp.1241-53, 1996.
DOI : 10.1016/S0002-9378(96)70667-1

R. Buller, M. Berman, J. Bloss, A. Manetta, and P. Disaia, Serum CA125 regression in epithelial ovarian cancer: Correlation with reassessment findings and survival, Gynecologic Oncology, vol.47, issue.1, pp.87-92, 1992.
DOI : 10.1016/0090-8258(92)90082-T

E. Banu, A. Banu, and J. Medioni, Serum PSA half-life as a predictor of survival for hormone-refractory prostate cancer patients: Modelization using a standardized set of response criteria, The Prostate, vol.27, issue.14, pp.1543-1552, 2007.
DOI : 10.1002/pros.20627

G. Toner, N. Geller, C. Tan, J. Nisselbaum, and G. Bosl, Serum tumor marker half-life during chemotherapy allows early prediction of complete response and survival in nonseminomatous germ cell tumors 1, Cancer Res, vol.50, pp.5904-5914, 1990.

A. Gregorakis, D. Malovrouvas, S. Stefanakis, K. Petraki, and A. Scorilas, Free/Total PSA (F/T ratio) kinetics in patients with clinically localized prostate cancer undergoing radical prostatectomy, Clinica Chimica Acta, vol.357, issue.2, pp.196-201, 2005.
DOI : 10.1016/j.cccn.2005.03.027

T. Stamey, J. Kabalin, and J. Mcneal, Prostate specific antigen in the diagnosis and treatment of adenocarcinoma of the prostate. II. Radical prostatectomy treated patients, JUrol, vol.141, pp.1076-83, 1989.

C. Yedema, P. Kenemans, and F. Voorhorst, CA 125 half-life in ovarian cancer: a multivariate survival analysis, British Journal of Cancer, vol.67, issue.6, pp.1361-1368, 1993.
DOI : 10.1038/bjc.1993.252

M. Rapellino, P. Piantino, and F. Pecchio, Disappearance curves of tumor markers after radical surgery, Int J Biol Markers, vol.9, pp.33-40, 1994.

M. May, S. Gunia, C. Helke, K. Braun, S. Pickenhain et al., Is it possible to provide a prognosis after radical prostatectomy for prostate cancer by means of a PSA regression model?, The International Journal of Biological Markers, vol.20, issue.2, pp.112-120, 2005.
DOI : 10.5301/JBM.2008.5665

A. Gadducci, S. Cosio, A. Fanucchi, S. Negri, R. Cristofani et al., The predictive and prognostic value of serum CA 125 half-life during paclitaxel/platinum-based chemotherapy in patients with advanced ovarian carcinoma, Gynecologic Oncology, vol.93, issue.1, pp.131-137, 2004.
DOI : 10.1016/j.ygyno.2003.12.043

A. Gadducci, P. Zola, and F. Landoni, Serum Half-Life of CA 125 during Early Chemotherapy as an Independent Prognostic Variable for Patients with Advanced Epithelial Ovarian Cancer: Results of a Multicentric Italian Study, Gynecologic Oncology, vol.58, issue.1, pp.42-49, 1995.
DOI : 10.1006/gyno.1995.1181

M. Hanninen, P. Venner, and S. North, A rapid PSA half-life following docetaxel chemotherapy is associated with improved survival in hormone refractory prostate cancer, Canadian Urological Association Journal, vol.3, issue.5, pp.369-74, 2009.
DOI : 10.5489/cuaj.1145

A. Mano, I. Godinho, and A. Falcao, CA 125 half-life breakpoint between a ???good??? and ???poor??? prognosis in patients with ovarian cancer, International Journal of Gynecology & Obstetrics, vol.15, issue.(2), pp.333-338, 2005.
DOI : 10.1016/j.ijgo.2004.12.028

A. Gerl, R. Lamerz, C. Clemm, K. Mann, R. Hartenstein et al., Does serum tumor marker half-life complement pretreatment risk stratification in metastatic nonseminomatous germ cell tumors?, Clin Cancer Res, vol.2, pp.1565-70, 1996.

V. Ravery, A. Meulemans, and L. Boccon-gibod, Clearance of Free and Total Serum PSA after Prostatic Surgery, European Urology, vol.33, issue.3, pp.251-255, 1998.
DOI : 10.1159/000019576

J. Oesterling, D. Chan, and J. Epstein, Prostate specific antigen in the preoperative and postoperative evaluation of localized prostatic cancer treated with radical prostatectomy, JUrol, vol.139, pp.766-72, 1988.

F. Haab, A. Meulemans, L. Boccon-gibod, M. Dauge, and V. Delmas, Clearance of serum PSA after open surgery for benign prostatic hypertrophy, radical cystectomy, and radical prostatectomy, The Prostate, vol.149, issue.6, pp.334-342, 1995.
DOI : 10.1002/pros.2990260609

P. Lange, N. Vogelzang, A. Goldman, B. Kennedy, and E. Fraley, Marker half-life analysis as a prognostic tool in testicular cancer, J Urol, vol.128, pp.708-719, 1982.

B. Murphy, R. Motzer, and M. Mazumdar, Serum tumor marker decline is an early predictor of treatment outcome in germ cell tumor patients treated with cisplatin and ifosfamide salvage chemotherapy, Cancer, vol.10, issue.10, pp.2520-2526, 1994.
DOI : 10.1002/1097-0142(19940515)73:10<2520::AID-CNCR2820731012>3.0.CO;2-R

S. Inanc, R. Meral, E. Darendeliler, V. Yasasever, and H. Onat, Prognostic Significance of Marker Half-life during Chemotherapy in Non-seminomatous Germ Cell Testicular Tumors, Acta Oncologica, vol.16, issue.8
DOI : 10.1002/1097-0142(19940515)73:10<2520::AID-CNCR2820731012>3.0.CO;2-R

R. Motzer, M. Mazumdar, D. Bajorin, G. Bosl, P. Lyn et al., High-dose carboplatin, etoposide, and cyclophosphamide with autologous bone marrow transplantation in first-line therapy for patients with poor-risk germ cell tumors., Journal of Clinical Oncology, vol.15, issue.7, pp.2546-52, 1997.
DOI : 10.1200/JCO.1997.15.7.2546

S. Colakovic, V. Lukic, L. Mitrovic, S. Jelic, S. Susnjar et al., Prognostic value of CA125 kinetics and half-life in advanced ovarian cancer, Int J Biol Markers, vol.15, pp.147-52, 2000.

E. Brandle, O. Hautmann, and M. Bachem, Serum half-life time determination of free and total prostate-specific antigen following radical prostatectomy???a critical assessment, Urology, vol.53, issue.4, pp.722-752, 1999.
DOI : 10.1016/S0090-4295(98)00593-7

G. Zagars and A. Pollack, Kinetics of serum prostate-specific antigen after external beam radiation for clinically localized prostate cancer, Radiotherapy and Oncology, vol.44, issue.3, pp.213-234, 1997.
DOI : 10.1016/S0167-8140(97)00123-0

R. Vollmer and G. Montana, The dynamics of prostate-specific antigen after definitive radiation therapy for prostate cancer, Clin Cancer Res, vol.5, pp.4119-4144, 1999.

G. Zagars and A. Pollack, The fall and rise of prostate-specific antigen: Kinetics of serum prostate-specific antigen levels after radiation therapy for prostate cancer, Cancer, vol.1, issue.3, pp.832-874, 1993.
DOI : 10.1002/1097-0142(19930801)72:3<832::AID-CNCR2820720332>3.0.CO;2-6

I. Kaplan, R. Cox, and M. Bagshaw, A model of prostatic carcinoma tumor kinetics based on prostate specific antigen levels after radiation therapy, Cancer, vol.2, issue.2, pp.400-405, 1991.
DOI : 10.1002/1097-0142(19910715)68:2<400::AID-CNCR2820680231>3.0.CO;2-Z

R. Vollmer and P. Humphrey, Tumor Volume in Prostate Cancer and Serum Prostate-Specific Antigen, American Journal of Clinical Pathology, vol.119, issue.1, pp.80-89, 2003.
DOI : 10.1309/UNAQJTFPB1RQBQD4

J. Van-straalen, M. Bossens, T. De-reijke, and G. Sanders, Biological Half-Life of Prostate-Specific Antigen after Radical Prostatectomy, Clinical Chemistry and Laboratory Medicine, vol.32, issue.2, pp.53-58, 1994.
DOI : 10.1515/cclm.1994.32.2.53

M. Lein, B. Brux, and K. Jung, Elimination of Serum Free and Total Prostate-Specific Antigen after Radical Retropubic Prostatectomy, Clinical Chemistry and Laboratory Medicine, vol.35, issue.8, pp.591-596, 1997.
DOI : 10.1515/cclm.1997.35.8.591

A. Meek, T. Park, E. Oberman, and L. Wielopolski, A prospective study of prostate specific antigen levels in patients receiving radiotherapy for localized carcinoma of the prostate, International Journal of Radiation Oncology*Biology*Physics, vol.19, issue.3, pp.733-774, 1990.
DOI : 10.1016/0360-3016(90)90504-D

M. Ritter, E. Messing, T. Shanahan, S. Potts, R. Chappell et al., Prostate-specific antigen as a predictor of radiotherapy response and patterns of failure in localized prostate cancer., Journal of Clinical Oncology, vol.10, issue.8, pp.1208-1225, 1992.
DOI : 10.1200/JCO.1992.10.8.1208

A. Hanlon, D. Moore, and G. Hanks, Modeling postradiation prostate specific antigen level kinetics, Cancer, vol.6, issue.1, pp.130-134, 1998.
DOI : 10.1002/(SICI)1097-0142(19980701)83:1<130::AID-CNCR17>3.0.CO;2-Y

R. Malik, A. Jani, and S. Liauw, Prostate-Specific Antigen Halving Time While on Neoadjuvant Androgen Deprivation Therapy Is Associated With Biochemical Control in Men Treated With Radiation Therapy for Localized Prostate Cancer, International Journal of Radiation Oncology*Biology*Physics, vol.79, issue.4, 2010.
DOI : 10.1016/j.ijrobp.2009.12.029

J. Riedinger, N. Eche, J. Basuyau, I. Dalifard, K. Hacene et al., Prognostic value of serum CA 125 bi-exponential decrease during first line paclitaxel/platinum chemotherapy: A French multicentric study, Gynecologic Oncology, vol.109, issue.2, pp.194-202, 2008.
DOI : 10.1016/j.ygyno.2008.01.035

R. Buller, M. Berman, J. Bloss, A. Manetta, and P. Disaia, CA 125 regression: A model for epithelial ovarian cancer response, American Journal of Obstetrics and Gynecology, vol.165, issue.2, pp.360-367, 1991.
DOI : 10.1016/0002-9378(91)90093-7

J. Markowska, G. Manys, and Z. Szewierski, CA 125 in monitoring clinical course in ovarian cancer patients. A prospective clinical study, Eur J Gynaecol Oncol, vol.13, pp.201-205, 1992.

R. Motzer, M. Mazumdar, and S. Gulati, Phase II Trial of High-Dose Carboplatin and Etoposide With Autologous Bone Marrow Transplantation in First-Line Therapy for Patients With Poor-Risk Germ Cell Tumors, JNCI Journal of the National Cancer Institute, vol.85, issue.22, pp.1828-1863, 1993.
DOI : 10.1093/jnci/85.22.1828

N. Vogelzang, P. Lange, A. Goldman, R. Vessela, E. Fraley et al., Acute changes of alpha-fetoprotein and human chorionic gonadotropin during induction chemotherapy of germ cell tumors, Cancer Res, vol.42, pp.4855-61, 1982.

M. Stevens, A. Norman, D. Dearnaley, and A. Horwich, Prognostic significance of early serum tumor marker half-life in metastatic testicular teratoma., Journal of Clinical Oncology, vol.13, issue.1, pp.87-92, 1995.
DOI : 10.1200/JCO.1995.13.1.87

M. Mazumdar, D. Bajorin, J. Bacik, G. Higgins, R. Motzer et al., Predicting Outcome to Chemotherapy in Patients With Germ Cell Tumors: The Value of the Rate of Decline of Human Chorionic Gonadotrophin and Alpha-Fetoprotein During Therapy, Journal of Clinical Oncology, vol.19, issue.9, pp.2534-2575, 2001.
DOI : 10.1200/JCO.2001.19.9.2534

S. Yuan, Z. Zhou, and D. Wan, The role of half-life of carcinoembryonic antigen (CEA) in prognosis prediction of colorectal cancer patients with preoperatively elevated CEA

F. Konishi, CEA Doubling Time and CEA Half-life in the Prediction of Recurrences after Colorectal Cancer Surgery, Japanese Journal of Clinical Oncology, vol.32, issue.2, pp.41-43, 2002.
DOI : 10.1093/jjco/hyf018

J. Choi and J. Min, Significance of postoperative serum level of carcinoembryonic antigen (CEA) and actual half life of CEA in colorectal cancer patients, Yonsei Medical Journal, vol.38, issue.1, pp.1-7, 1997.
DOI : 10.3349/ymj.1997.38.1.1

R. Ellis, A. Vertocnik, and B. Sodee, Combination conformal radiotherapy and radioimmunoguided transperineal 103Pd implantation for patients with intermediate and unfavorable risk prostate adenocarcinoma, Brachytherapy, vol.2, issue.4, pp.215-237, 2003.
DOI : 10.1016/j.brachy.2003.12.002

J. Crook, E. Szumacher, S. Malone, S. Huan, and R. Segal, Intermittent androgen suppression in the management of prostate cancer, Urology, vol.53, issue.3, pp.530-534, 1999.
DOI : 10.1016/S0090-4295(98)00547-0

S. Ueno, M. Namiki, T. Fukagai, H. Ehara, M. Usami et al., Efficacy of primary hormonal therapy for patients with localized and locally advanced prostate cancer: A retrospective multicenter study, International Journal of Urology, vol.169, issue.12, pp.1494-500, 2006.
DOI : 10.1111/j.1442-2042.2006.01604.x

D. Richardson, L. Seamon, and M. Carlson, CA125 decline in ovarian cancer patients treated with intravenous versus intraperitoneal platinum-based chemotherapy, Gynecologic Oncology, vol.111, issue.2, pp.233-239, 2008.
DOI : 10.1016/j.ygyno.2008.07.035

G. Frasci, S. Conforti, and F. Zullo, A risk model for ovarian carcinoma patients using CA 125: Time to normalization renders second-look laparotomy redundant, Cancer, vol.9, issue.6, pp.1122-1152, 1996.
DOI : 10.1002/(SICI)1097-0142(19960315)77:6<1122::AID-CNCR18>3.0.CO;2-3

M. Schmitz, G. Padula, P. Chun, and A. Davis, Normalization of prostate specific antigen in patients treated with intensity modulated radiotherapy for clinically localized prostate cancer, Radiation Oncology, vol.5, issue.1, p.80, 2010.
DOI : 10.1186/1748-717X-5-80

K. Fizazi, S. Culine, and A. Kramar, Early Predicted Time to Normalization of Tumor Markers Predicts Outcome in Poor-Prognosis Nonseminomatous Germ Cell Tumors, Journal of Clinical Oncology, vol.22, issue.19, pp.3868-76, 2004.
DOI : 10.1200/JCO.2004.04.008

M. Mego, K. Rejlekova, and M. Reckova, Kinetics of tumor marker decline as an independent prognostic factor in patients with relapsed metastatic germ-cell tumors., Neoplasma, vol.56, issue.5, pp.398-403, 2009.
DOI : 10.4149/neo_2009_05_398

H. Tsuda, Y. Hashiguchi, and S. Nakata, The CA125 regression rate to predict overall survival differ between paclitaxel-containing regimen and nonpaclitaxel regimen in patients with advanced ovarian cancer, International Journal of Gynecological Cancer, vol.12, issue.5, pp.435-442, 2002.
DOI : 10.1046/j.1525-1438.2002.01133.x

A. Mano, A. Falcao, and I. Godinho, CA-125 AUC as a new prognostic factor for patients with ovarian cancer, Gynecologic Oncology, vol.97, issue.2, pp.529-563, 2005.
DOI : 10.1016/j.ygyno.2005.01.040

G. Cappelli, Mathematical model application to the kinetic study of tumor markers, Int J Biol Markers, vol.9, pp.8-14, 1994.

. Beal, . Sl, . Sheiner, . Lb, and A. Boeckmann, NONMEM users guides, Icon Development Solutions, 2006.

E. Ette and P. Williams, Population Pharmacokinetics I: Background, Concepts, and Models, Annals of Pharmacotherapy, vol.32, issue.10, pp.1702-1708, 2004.
DOI : 10.1007/978-1-4613-3255-8_15

L. Sheiner, The Population Approach to Pharmacokinetic Data Analysis: Rationale and Standard Data Analysis Methods, Drug Metabolism Reviews, vol.27, issue.1-2, pp.153-71, 1984.
DOI : 10.1214/aoms/1177706645

B. You, P. Perrin, and G. Freyer, Advantages of prostate-specific antigen (PSA) clearance model over simple PSA half-life computation to describe PSA decrease after prostate adenomectomy, Clinical Biochemistry, vol.41, issue.10-11, pp.785-95, 2008.
DOI : 10.1016/j.clinbiochem.2008.04.001
URL : https://hal.archives-ouvertes.fr/hal-00756369

B. You, P. Girard, and P. Paparel, Prognostic value of modeled PSA clearance on biochemical relapse free survival after radical prostatectomy, The Prostate, vol.34, issue.12, pp.1325-1358, 2009.
DOI : 10.1002/pros.20978

B. You, L. Fronton, and H. Boyle, Predictive Value of Modeled AUCAFP-hCG, a Dynamic Kinetic Parameter Characterizing Serum Tumor Marker Decline in Patients With Nonseminomatous Germ Cell Tumor, Urology, vol.76, issue.2, pp.423-432, 2010.
DOI : 10.1016/j.urology.2010.02.049

B. You, M. Pollet-villard, and L. Fronton, Predictive values of hCG clearance for risk of methotrexate resistance in low-risk gestational trophoblastic neoplasias, Annals of Oncology, vol.21, issue.8, pp.1643-50, 2010.
DOI : 10.1093/annonc/mdq033
URL : https://hal.archives-ouvertes.fr/hal-00756357

K. Brendel, C. Dartois, and E. Comets, Are Population Pharmacokinetic and/or Pharmacodynamic Models Adequately Evaluated?, Clinical Pharmacokinetics, vol.33, issue.3, pp.221-255, 2002.
DOI : 10.2165/00003088-200746030-00003
URL : https://hal.archives-ouvertes.fr/inserm-00159124

C. Dartois, K. Brendel, and E. Comets, Overview of model-building strategies in population PK/PD analyses: 2002???2004 literature survey, British Journal of Clinical Pharmacology, vol.4, issue.5, pp.603-615, 2007.
DOI : 10.1007/s10928-006-9046-9
URL : https://hal.archives-ouvertes.fr/inserm-00159122

Y. Yano, S. Beal, and L. Sheiner, Evaluating pharmacokinetic/pharmacodynamic models using the posterior predictive check, JPharmacokinetPharmacodyn, vol.28, pp.171-92, 2001.

R. Norman, M. Buchholz, A. Somogyi, and F. Amato, hCGbeta core fragment is a metabolite of hCG: evidence from infusion of recombinant hCG, Journal of Endocrinology, vol.164, issue.3, pp.299-305, 2000.
DOI : 10.1677/joe.0.1640299

W. De, L. Collette, and R. Sylvester, Serum alpha-fetoprotein surge after the initiation of chemotherapy for non-seminomatous testicular cancer has an adverse prognostic significance, BrJ Cancer, vol.78, pp.1350-1355, 1998.

A. Horwich and M. Peckham, Transient tumor marker elevation following chemotherapy for germ cell tumors of the testis, Cancer TreatRep, vol.70, pp.1329-1360, 1986.

H. Sonoo and J. Kurebayashi, Serum tumor marker kinetics and the clinical course of patients with advanced breast cancer, Surgery Today, vol.71, issue.4, pp.250-257, 1996.
DOI : 10.1007/BF00311583

S. Wu, F. Chou, and K. Rau, Clinical significance of a serum CA 15-3 surge and the usefulness of CA 15-3 kinetics in monitoring chemotherapy response in patients with metastatic breast cancer, Breast Cancer Research and Treatment, vol.72, issue.3, 2010.
DOI : 10.1007/s10549-010-1117-3

H. Kim, K. Lee, and Y. Kim, Chemotherapy-induced transient CEA and CA19-9 surges in patients with metastatic or recurrent gastric cancer, Acta Oncologica, vol.20, issue.3, pp.385-90, 2009.
DOI : 10.1093/jjco/29.11.550

R. Sotelo, K. Mora, and L. Perez, Assay Standardization Bias: Different Prostate Cancer Detection Rates and Clinical Outcomes Resulting from Different Assays for Free and Total Prostate-Specific Antigen, Urology, vol.69, issue.6, pp.1143-1149, 2007.
DOI : 10.1016/j.urology.2007.02.006

S. Loeb, D. Chan, and L. Sokoll, Prostate Specific Antigen Assay Standardization Bias Could Affect Clinical Decision Making, The Journal of Urology, vol.180, issue.5, pp.1959-62, 2008.
DOI : 10.1016/j.juro.2008.07.036

M. Evans, O. Brien, J. Dvorin, E. Wapner, R. Harrison et al., Standardization of Methods Reduces Variability: Explanation for Historical Discrepancies in Biochemical Screening, Genetic Testing, vol.7, issue.1, pp.81-84, 2003.
DOI : 10.1089/109065703321561001

E. Tso, P. Elson, F. Vanlente, and M. Markman, The ???real-life??? variability of CA-125 in ovarian cancer patients, Gynecologic Oncology, vol.103, issue.1, pp.141-145, 2006.
DOI : 10.1016/j.ygyno.2006.02.010

A. Pilo, G. Zucchelli, R. Cohen, M. Chiesa, and C. Bizollon, Performance of Immunoassays for CA 19-9, CA 15-3 and CA 125 Tumour Markers Evaluated from an International Quality Assessment Survey, Clinical Chemistry and Laboratory Medicine, vol.34, issue.2, pp.145-50, 1996.
DOI : 10.1515/cclm.1996.34.2.145

B. Gronlund, H. Hansen, C. Hogdall, E. Hogdall, and S. Engelholm, Do CA125 response criteria overestimate tumour response in second-line treatment of epithelial ovarian carcinoma?, British Journal of Cancer, vol.90, issue.2, pp.377-82, 2004.
DOI : 10.1038/sj.bjc.6601501

C. Peters-engl, A. Obermair, H. Heinzl, P. Buxbaum, P. Sevelda et al., CA 125 regression after two completed cycles of chemotherapy: lack of prediction for long-term survival in patients with advanced ovarian cancer, British Journal of Cancer, vol.81, issue.4, pp.662-668, 1999.
DOI : 10.1038/sj.bjc.6690744

F. Vicini, C. Vargas, A. Abner, L. Kestin, E. Horwitz et al., LIMITATIONS IN THE USE OF SERUM PROSTATE SPECIFIC ANTIGEN LEVELS TO MONITOR PATIENTS AFTER TREATMENT FOR PROSTATE CANCER, The Journal of Urology, vol.173, issue.5, pp.1456-62, 2005.
DOI : 10.1097/01.ju.0000157323.55611.23

G. Toner, Early Identification of Therapeutic Failure in Nonseminomatous Germ Cell Tumors by Assessing Serum Tumor Marker Decline During Chemotherapy: Still Not Ready for Routine Clinical Use, Journal of Clinical Oncology, vol.22, issue.19, pp.3842-3847, 2004.
DOI : 10.1200/JCO.2004.06.923

A. Sostelly, E. Henin, B. You, P. Girard, and M. Karlsson, Simultaneous modelling of PSA in BPH and cancer patients treated by prostate surgery, Proceedings of 2009 Annual Congress of Population Apprach Group in Europe Abs 1497